Vir Biotechnology (VIR) closed at $12.21 on November 6, 2026, up 10.8% from the previous close, on volume of 1,736,801 shares (30-day average 1,785,824).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Jelly Roll or Calendar Double Straddle | 16-Oct-2610 P : 10 C|20-Nov-2610 P : 10 C | 2,000 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Bank of America Securities Remains a Buy on Vir Biotechnology (VIR)
TipRanks (Fri, 6-Nov 7:59 AM ET)
Evercore ISI Reaffirms Their Buy Rating on Vir Biotechnology (VIR)
TipRanks (Thu, 5-Nov 5:48 PM ET)
Business Wire (Thu, 5-Nov 10:00 AM ET)
Leerink Partners Sticks to Its Buy Rating for Vir Biotechnology (VIR)
TipRanks (Thu, 5-Nov 9:29 AM ET)
TD Cowen Reaffirms Their Buy Rating on Vir Biotechnology (VIR)
TipRanks (Thu, 5-Nov 9:08 AM ET)
Morgan Stanley Sticks to Their Buy Rating for Vir Biotechnology (VIR)
TipRanks (Thu, 5-Nov 8:47 AM ET)
Barclays Sticks to Its Buy Rating for Vir Biotechnology (VIR)
TipRanks (Thu, 5-Nov 3:41 AM ET)
Vir Biotechnology Non-GAAP EPS of -$0.57 beats by $0.18
Seeking Alpha News (Wed, 4-Nov 5:01 PM ET)
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Business Wire (Wed, 4-Nov 4:05 PM ET)
Vir Biotechnology Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 3-Nov 5:35 PM ET)
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Vir Biotechnology trades on the NASDAQ stock market under the symbol VIR.
As of November 6, 2026, VIR stock price climbed to $12.21 with 1,736,801 million shares trading.
VIR has a beta of 1.10, meaning it tends to be more sensitive to market movements. VIR has a correlation of 0.06 to the broad based SPY ETF.
VIR has a market cap of $1.97 billion. This is considered a Small Cap stock.
Last quarter Vir Biotechnology reported $-188,000 in Revenue and -$.57 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.19.
In the last 3 years, VIR traded as high as $14.45 and as low as $4.16.
The top ETF exchange traded funds that VIR belongs to (by Net Assets): IJR, VTI, IWM, VB, XBI.
VIR has outperformed the market in the last year with a price return of +138.5% while the SPY ETF gained +10.8%. VIR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +39.3% and +15.5%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
VIR support price is $10.58 and resistance is $11.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VIR shares will trade within this expected range on the day.
